Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine-Samidorphan in Adults With Schizophrenia
NCT06649214Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
A Phase 3 trial of olanzapine + samidorphan in schizophrenia, sponsored by Qilu Pharmaceutical. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06649214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649214.